Cancers: Efficacy of conventional therapy (CT, chemotherapy with or without targeted therapy) after treatment failure in dMMR/MSI metastatic colorectal cancer (mCRC)

Mismatch repair deficient/microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) with immune checkpoint inhibitor (ICI) progression followed by conventional therapy (CT, chemotherapy with or without targeted therapy) efficacy is unclear
.

Mismatch repair deficient/microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) with immune checkpoint inhibitor (ICI) progression followed by conventional therapy (CT, chemotherapy with or without targeted therapy) efficacy is unclear
.

Therefore, foreign researchers have carried out relevant studies to evaluate the efficacy of CT therapy after treatment failure in dMMR/MSI metastatic colorectal cancer (mCRC)
.

The results were published in the journal Cancers

Therefore, foreign researchers have carried out relevant studies to evaluate the efficacy of CT therapy after treatment failure in dMMR/MSI metastatic colorectal cancer (mCRC)

A total of 31 dMMR/MSI mCRC patients were enrolled from June 2015 to January 2020
.

Median age was 56 years and 58% of patients had ECOG 0-1 when treatment was started after progression on ICI therapy

A total of 31 dMMR/MSI mCRC patients were enrolled from June 2015 to January 2020

Prior to ICI treatment, 48% of patients received targeted therapy with two or more chemotherapy regimens, and 100%, 94%, and 68% were exposed to fluorouracil, oxaliplatin, and irinotecan, respectively

In ICI therapy, 71% of patients (anti-PD-1, n = 15, anti-PDL-1, n = 7) were treated with anti-PD(L)-1 monotherapy, and 9 patients were treated with combination therapy

The main chemotherapy regimens used after ICI treatment were FOLFOX (29%), FOLFIRI (29%) or trifluridine (16%), concomitant use of anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) The monoclonal antibody regimens were 39% and 19%, respectively

The median follow-up time after ICI progression was 23.
8 months, and the DCR was 45%, including 4 cases of PR and 10 cases of SD
.

Median PFS and OS were 2.

The median follow-up time after ICI progression was 23.

Prognostic factors found that only ECOG ≧2 was associated with worse PFS (HR=2.
22, 95%CI 1.
03, 4.
77, p=0.
045), but not OS
.

Prognostic factors found that only ECOG ≧2 was associated with worse PFS (HR=2.
22, 95%CI 1.
03, 4.
77, p=0.
045), but not OS
.

In summary, the study shows that previous ICI treatment does not enhance the efficacy of subsequent traditional treatment, but the sample size is limited, and further verification is required in the follow-up
.

In summary, the study shows that previous ICI treatment does not enhance the efficacy of subsequent traditional treatment, but the sample size is limited, and further verification is required in the follow-up
.

Studies have shown that previous ICI treatment does not enhance the efficacy of subsequent traditional treatment, but the sample size is limited, and further verification is needed in the future

Original source:

Original source:

Bui, QL; Mas, L.
; Hollebecque, A.
; Tougeron, D.
; de la Fochardière, C.
; Pudlarz, T.
; Alouani, E.
; Guimbaud, R.
; Taieb, J.
; André, T.
; et al.
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer.
Cancers 2022, 14,406.
https://doi.
org/10.
3390/cancers14020406

Bui, QL; Mas, L.
; Hollebecque, A.
; Tougeron, D.
; de la Fochardière, C.
; Pudlarz, T.
; Alouani, E.
; Guimbaud, R.
; Taieb, J.
; André, T.
; et al.
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer.
Cancers 2022, 14, 406.
 https://doi.
org/10.
3390/cancers14020406 https://doi.
org/10.
3390/ https :/ /doi.
org/10.
3390/ leave a message here